EAElizabeth Helen Aitken

Elizabeth Helen Aitken

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elizabeth Helen Aitken has a total of 159 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Afucosylated VAR2CSA-Specific IgG Reduces Risks of Placental Malaria

    by Honghua Ding, Oscar H Lloyd Williams, Maria Saeed, Wina Hasang, Bruce D Wines, Mary Lopez-Perez, Maria del Pilar Quintana, Lars Hviid, Adam Wheatley, Mwayiwawo Madanitsa, et al.

    Background: Antibody Fc regions have important roles in clearance of Plasmodium falciparum-infected erythrocytes. One such role is engagement with Fcγ receptors on host leukocytes. In the case of FcγRIIIa and b, this interaction is greatly enhanced when the IgG glycan is afucosylated. Methods: In this study, we used a fucose-sensitive enzyme-linked immunosorbent assay (FEASI) to assess afucosylation in IgG specific for placental malaria protein VAR2CSA from n = 139 malaria-exposed pregnant Malawian women, correlating these data with mass spectrometry-based analysis. Furthermore, we measured the effect of afucosylation on Fc-mediated leukocyte functions, using both plasma and a monoclonal antibody, PAM2.8, with varying levels of afucosylation. Results: There were significantly higher levels of VAR2CSA-specific IgG afucosylation in women with no placental malaria measured by FEASI (P < .0001), which correlated strongly with mass spectrometry analysis (R = 0.8, P < .0001). In addition, highly afucosylated IgG mediated significantly greater neutrophil phagocytosis of antigen-coated beads and induction of NK cell degranulation by infected erythrocytes. Conclusions: Afucosylated IgG to VAR2CSA, measured by FEASI or mass spectrometry, was a correlate of protection from placental malaria, and afucosylated IgG activated NK cells and neutrophils. Naturally acquired or therapeutic afucosylated IgG antibody could have a role in protection from malaria infection.

  • Open Access

    Novel monoclonal antibodies targeting distinct sites on placental binding P. falciparum antigen VAR2CSA synergistically enhance parasite phagocytosis

    by Vivin R. Kokuhennadige, Christopher A. Gonelli, Oscar H. Lloyd Williams, Robyn Esterbauer, Andrew Kelly, Wina Hasang, Holger W. Unger, Paula Tesine, Alice Mengi, Benishar Kombut, et al.

    Placental malaria, due to the sequestration of Plasmodium falciparum -infected erythrocytes (IE), causes adverse pregnancy outcomes. The sequestration is mediated by VAR2CSA, a protein that binds to placental chondroitin sulfate A (CSA). VAR2CSA antibodies protect against adverse pregnancy outcomes; however, no licensed VAR2CSA-based vaccine or therapeutic exists to date. We identified and expressed VAR2CSA-specific IgG1 monoclonal antibodies (mAbs) using B cells of malaria-exposed Papua New Guinean women. VAR2CSA mAbs were characterised by their ability to recognise eight heterologous CSA-binding P. falciparum strains, to neutralise CSA binding and/or to induce phagocytosis of IEs by THP-1 monocytes. We identified 16 mAbs, all of which targeted just two of the six domains of VAR2CSA, DBL3X and DBL5ε. Cross-reactivity varied between mAbs, but was highest among mAbs to DBL5ε, with four of eight of these mAbs binding to all eight strains. Although individual mAbs did not promote phagocytosis, combinations of mAbs recognising distinct epitopes either on the same domain or over different domains did. None of the mAbs inhibited IEs from binding to CSA. Our findings suggest that a combination of mAbs recognising more than one epitope would be needed for a therapeutic aiming to promote parasite clearance by phagocytosis; that DBL5ε could be considered for a VAR2CSA vaccine that aims to elicit cross-reactive antibodies that promote phagocytosis; and that identification of binding-inhibitory mAbs requires thoughtful B-cell bait design.

  • Open Access

    Antibody-Dependent Neutrophil Phagocytosis of Plasmodium falciparum –Infected Erythrocytes Is Mediated by FcγRIIa

    by Maria Saeed, Elizabeth H Aitken, Bruce D Wines, Stephen J Rogerson

    Fc gamma receptor III b (FcγRIIIb), a glycosylphosphatidylinositol-linked receptor, is the most abundant neutrophil FcγR on neutrophils, followed by FcγRIIa. FcγRs interact with IgG, and studies have reported the association of antibody-dependent neutrophil phagocytosis (ADNP) with protection against malaria; however, the role of specific FcγRs is not clear. To investigate the relative importance of FcγRIIIb and FcγRIIa as mediators of the ADNP of Plasmodium falciparum–infected erythrocytes, purified neutrophils from healthy donors were treated with tumor necrosis factor (TNF) to mobilize the intracellular stores of FcγRIIIb to the surface, followed by enzymatic cleavage of glycosylphosphatidylinositol-linked FcγRIIIb with phosphatidylinositol phospholipase C (PIPLC). In TNF/PIPLC-treated neutrophils, detectable FcγRIII decreased by 79% (relative geometric mean fluorescence intensity, 21 ± 4.5 [mean ± SD]), while FcγRIIa detection increased by 82% (182 ± 2.3) as compared with untreated neutrophils (100%). When opsonized infected erythrocytes were incubated with TNF/PIPLC-treated neutrophils, ADNP by FcγRIIIb-depleted neutrophils increased significantly (relative phagocytosis, 585% ± 108%) as compared with untreated neutrophils (100%, P = .042). Using FcγR blocking, we show that when compared with no blocker (relative phagocytosis, 100%), ADNP was reduced >5-fold by FcγRIIa blocker alone (∼17% ± 1.5%, P < .05) and to a similar extent by combined FcγRIIa and FcγRIII blockers (∼24% ± 5.5%, P < .05). Our data suggest that FcγRIIa is the main phagocytic receptor that mediates the ADNP of infected erythrocytes and that FcγRIIIb acts as a decoy receptor.


  • Open Access

    VAR2CSA-specific IgG and IgM antibodies are markers of exposure and protection against adverse malaria pregnancy outcomes

    by Akachukwu M. Onwuka, Elizabeth H. Aitken, Wina Hasang, Mwayiwawo Madanitsa, Victor Mwapasa, Kamija Phiri, Feiko O. ter Kuile, Stephen J. Rogerson

    Background: Placental malaria is caused by the binding of the Plasmodium falciparum erythrocyte membrane protein 1 ( Pf EMP1) protein VAR2CSA, found on the surface of infected erythrocytes, to placental tissue. Complications include maternal anaemia, low birth weight, small for gestational age and preterm delivery. Acquisition of antibodies against VAR2CSA during pregnancy has been linked to immunity against infection. Methods: Pregnant Malawian women were enrolled at their first antenatal care visit at 16–28 weeks’ gestation into a trial of malaria prevention. Women with malaria infection at enrolment (n = 321) or any later point in pregnancy (n = 145) were selected. The IgG and IgM plasma levels against the VAR2CSA DBL1X-ID2a domain were measured at enrolment and delivery. Associations between the DBL1X-ID2a VAR2CSA-specific IgG and IgM antibody levels at enrolment or delivery and low birth weight, small for gestational age, maternal anaemia at delivery, and preterm delivery were assessed using logistic regression with confounder adjustment. Result: Women with malaria infection at enrolment had higher antibody levels to DBL1X-ID2a than uninfected women, and these declined from enrolment to delivery. There were no significant associations between the IgG antibody level measured at enrolment and the birth outcomes of interest, but the IgG antibody level at delivery in women uninfected at enrolment was associated with a lower risk of low birth weight, adjusted odds ratio (aOR) 0.43 (95% CI 0.19–0.97) p = 0.04. Additionally, in women infected at enrolment, one log higher IgM antibodies to DBL1X-ID2a VAR2CSA at enrolment were associated with a significant 23% decrease in maternal anaemia at delivery, aOR 0.77 (95% CI 0.60–0.99), p = 0.04. Conclusion: VAR2CSA-specific IgG and IgM antibodies are markers of malaria infection and protection against placental malaria outcomes.


  • Open Access

    Association of a novel IgG3 allele with malaria in children from the Sepik region of Papua New Guinea

    by Maria Saeed, Elizabeth H Aitken, Myo T Naung, Caitlin Bourke, Kenneth W Wu, Rhea J Longley, Amy W Chung, Timon Damelang, Benson Kiniboro, Ivo Mueller, et al.

    Background: Susceptibility to malaria can be influenced by host genetic factors, including immune response genes. Antibodies against Plasmodium antigens are known to play an important role in protection from clinical disease. Polymorphisms in these antibodies may result in different functional properties that could provide protection from malaria. Methods: Immunoglobulin G1 (IgG1) and IgG3 alleles and IgG3 hinge region were investigated by polymerase chain reaction (PCR) and Sanger sequencing in a longitudinal cohort of children aged 1-3 years (N=203) from East Sepik region of Papua New Guinea (PNG). Linear regression was used to investigate associations between immunoglobulin alleles and Plasmodium infections. Results: Seventy-eight percent of the children were either heterozygous (n=82, 40%) or homozygous (n=77, 38%) for IGHG3*30 (G3m29), a novel IgG3 allele. G3m29 has a long hinge region of 4 exons. Significantly fewer Plasmodium spp. infections were observed in children with the IGHG3*30 allele compared to children without the allele (β= -1.736, 95% CI [-3.39, -0.079], p=0.038). This effect was most noticeable for Plasmodium vivax asymptomatic infections as IGHG3*30 carriers had on average one fewer infection in the 18-month follow-up period as compared to non-IGHG3*30 allele carriers (β= -1.06; 95% CI [-2.01, -0.12], p=0.028). Additionally, IGHG3*30 allele carriers had significantly lower levels of IgG to P. vivax vaccine candidate proteins compared to non-IGHG3*30 allele carriers. Conclusions: The IGHG3*30 allele is highly prevalent in the East Sepik region and is associated with fewer Plasmodium spp. infections.


  • Open Access

    A whole blood assay for antibody dependent phagocytosis of Plasmodium falciparum infected erythrocytes

    by Dilini Rathnayake, Wina Hasang, Alexander Macpherson, HongHua Ding, Laurens Manning, Moses Laman, Maria Ome-Kaius, Holger W. Unger, Feiko Ter Kuile, Mwayi Madanitsa, et al.

    Background: Antibodies are used to protect against Plasmodium falciparum malaria. One antibody target, the variant surface antigens, is expressed on infected erythrocytes (IEs). Antibodies to these antigens can either block IE sequestration in the tissues, facilitate natural killer cell-mediated killing, or opsonise IEs for phagocytic clearance by neutrophils and monocytes. Methods: We developed a high-throughput assay to measure antibody-dependent neutrophil phagocytosis (ADNP) and antibody-dependent cellular phagocytosis (ADCP, by blood monocytes) in the same sample of fresh whole blood. Results: Here we show that immune plasma mediates ADNP and ADCP in a concentration-dependent manner. Uptake is greater in the presence of complement proteins and is largely dependent on the expression of P. falciparum Erythrocyte Membrane Protein 1 located on the IE surface. Plasma from pregnant Papua New Guinean women with and without placental malaria shows that ADNP and ADCP are associated with protection from placental malaria. ADNP, but not ADCP, using IEs expressing IT4VAR19 (a PfEMP1 variant that binds to endothelial protein C receptor through a DC8 domain cassette) is higher at hospital presentation in children with uncomplicated malaria than in severe malaria. In pregnant women, ADNP and ADCP in whole blood are strongly correlated with one another (Spearman’s rho = 0.90), but not with ADNP or ADCP using purified neutrophils and monocytes in the absence of complement proteins. Conclusions: The whole blood assay is a powerful new tool to assess functional antibodies that may protect against P. falciparum malaria. It allows simultaneous measurement of phagocytosis of opsonised IEs by monocytes and neutrophils.


  • Open Access

    Ficolin-1 in pediatric Plasmodium falciparum malaria and its possible role in parasite clearance and anemia

    by Di Zheng, Natalie Ferrington, Dilini Rathnayake, Wina Hasang, Agersew Alemu, Visopo Harawa, Amalia Karahalios, Phoebe Fitzpatrick, Evelyne Gout, Nicole M. Thielens, et al.

    Plasmodium falciparum malaria causes significant disease, especially in young children. A successful immune response to P. falciparum is a major determinant of clinical outcome. The ficolins are a family of lectins that act as pattern recognition molecules and can activate the lectin complement pathway and may promote inflammation and facilitate opsonization and lysis of pathogens. Here, we have investigated the potential roles of ficolin-1 and ficolin-2 in the context of P. falciparum infection. We measured ficolin-1 and ficolin-2 concentrations in plasma from Malawian children presenting with uncomplicated or severe malaria or healthy controls (HCs) by ELISA. Using flow cytometry, we assessed whether ficolin-1 could bind to infected red blood cells (iRBCs) and whether it binds sialic acid on the iRBCs. Ficolin-1 and ficolin-2 plasma levels were measured in children from all clinical groups. Compared to HCs (reference), Ficolin-1 concentrations in plasma were higher in children with uncomplicated (geometric mean ratio: 1.88; 95% confidence interval [CI]: 1.25–2.82) and severe malaria (1.65; 95% CI: 1.10–2.46). Ficolin-1 levels were positively associated with peripheral blood monocyte (1.30; 1.02–1.67) and neutrophil counts (1.06; 1.00–1.13). Ficolin-2 was not associated with malaria. Hemoglobin levels were negatively associated with ficolin-1 (−0.38; −0.68 to –0.09) and ficolin-2 (−0.36; −0.68 to –0.04). Ficolin-1 bound more to iRBCs compared to uninfected RBCs, and binding was reduced in a ficolin-1 mutant that did not bind to sialic acid. These results highlight a largely overlooked role for ficolin-1 in the immune response to P. falciparum infection and point to a potential role for lectins contributing to parasite clearance and anaemia.

  • Malaria monoclonals block brain binding

    by Stephen J. Rogerson, Isobel S. Walker, Elizabeth H. Aitken

  • Open Access

    Intermittent preventive treatment with sulphadoxine-pyrimethamine but not dihydroartemisinin-piperaquine modulates the relationship between inflammatory markers and adverse pregnancy outcomes in Malawi

    by Kaylene Cheng, Elizabeth H. Aitken, Wina Hasang, Niamh Meagher, David J. Price, Mwayiwawo Madanitsa, Victor Mwapasa, Kamija S. Phiri, James Dodd, Feiko O. ter Kuile, et al.

    Women in malaria-endemic areas receive sulphadoxine-pyrimethamine (SP) as Intermittent Preventive Treatment in Pregnancy (IPTp) to reduce malaria. While dihydroartemisinin-piperaquine (DP) has superior antimalarial properties as IPTp, SP is associated with superior fetal growth. As maternal inflammation influences fetal growth, we investigated whether SP alters the relationship between inflammation and birth outcomes. We measured C-reactive protein (CRP) and alpha-1-acid glycoprotein (AGP) at enrollment (16–28 gestation weeks (gw)), visit 3 (24–36 gw) and delivery in 1319 Malawian women randomized to receive monthly SP, DP, or DP and single-dose azithromycin (AZ) in the IMPROVE trial (NCT03208179). Logistic regression was used to assess the relationship between adverse outcomes, inflammation, and treatment arm. Elevated AGP at enrollment was associated with adverse birth outcome (aRR 1.40, 95% CI: 1.15, 1.70), with similar associations observed across treatment arms, exceptions being that elevated AGP was associated with low maternal weight gain in SP recipients (aRR 1.94, 95% CI: 1.36, 2.76) and with small for gestational age in DP+AZ recepients (aRR 1.49, 95% CI 1.02, 2.17). At visit 3 there were few associations between inflammation andoutcomes. At delivery, women with elevated AGP receiving either DP or DP+AZ had an increased risk of adverse birth outcomes (aRR 1.60, 95% CI: 1.28, 2.00), including low birth weight, pre-term birth and foetal loss, this was not seen in women receiving SP (aRR 0.82, 95% CI: 0.54, 1.26). The risk of an association between elevated AGP and adverse birth outcome was higher in those receiving DP or DP+AZ compared to those receiving SP (aRR 1.95, 95% CI: 1.21, 3.13). No clear associations between CRP and adverse outcomes were observed. AGP identified women at risk of adverse pregnancy outcomes. SP modifies the relationship between inflammatory biomarkers and adverse outcomes. Our findings provide insights into potential mechanisms by which SP may improve pregnancy outcomes.


  • Navigating the terrain of neutrophil extracellular traps in severe malaria pathogenesis

    by Maria Saeed, Elizabeth H. Aitken, Stephen J. Rogerson